Samsung Biologics (KRX:207940) signed a contract worth 350.8 billion Korean won to provide contract manufacturing services to an undisclosed EU-based pharmaceutical company.
The contract runs from July 22, 2026, to Dec. 31, 2033, according to a Thursday filing with the Korea Exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.